BRPI0513850A - composição terapêutica com uma neurotoxina botulìnica - Google Patents
composição terapêutica com uma neurotoxina botulìnicaInfo
- Publication number
- BRPI0513850A BRPI0513850A BRPI0513850-7A BRPI0513850A BRPI0513850A BR PI0513850 A BRPI0513850 A BR PI0513850A BR PI0513850 A BRPI0513850 A BR PI0513850A BR PI0513850 A BRPI0513850 A BR PI0513850A
- Authority
- BR
- Brazil
- Prior art keywords
- neurotoxin
- therapeutic composition
- botulically
- present
- botulinum
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/86—Products or compounds obtained by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
COMPOSIçãO TERAPêUTICA COM UMA NEUROTOXINA BOTULìNICA A presente invenção diz respeito a composições farmacêuticas que compreendem uma neurotoxina botulínica de clostridium botulinum, a neurotoxina sendo livre das proteínas de formação de complexo naturalmente presentes no complexo de neurotoxina botulínica ou sendo quimicamente modificada por manipulação genética. Além disso, as composições farmacêuticas da atual invenção têm boa estabilidade e são formuladas, de forma vantajosa, livres de albumina sérica humana.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59119604P | 2004-07-26 | 2004-07-26 | |
PCT/US2005/025408 WO2006020208A2 (en) | 2004-07-26 | 2005-07-19 | Therapeutic composition whit a botulinum neurotoxin |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0513850A true BRPI0513850A (pt) | 2008-05-20 |
Family
ID=35355516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0513850-7A BRPI0513850A (pt) | 2004-07-26 | 2005-07-19 | composição terapêutica com uma neurotoxina botulìnica |
Country Status (17)
Country | Link |
---|---|
US (6) | US7879341B2 (pt) |
EP (3) | EP2266600B1 (pt) |
JP (3) | JP4907530B2 (pt) |
KR (3) | KR100852824B1 (pt) |
CN (2) | CN101005853B (pt) |
AU (1) | AU2005274822B2 (pt) |
BR (1) | BRPI0513850A (pt) |
CA (2) | CA2799413A1 (pt) |
EA (1) | EA011652B1 (pt) |
EC (1) | ECSP077197A (pt) |
ES (1) | ES2479515T3 (pt) |
HK (1) | HK1107670A1 (pt) |
IL (3) | IL180771A (pt) |
MX (1) | MX2007000794A (pt) |
NO (1) | NO20071043L (pt) |
WO (1) | WO2006020208A2 (pt) |
ZA (1) | ZA200700433B (pt) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
EP2364734B1 (en) * | 2000-07-21 | 2017-09-06 | ReVance Therapeutics, Inc. | Multi-component biological transport systems |
US7763663B2 (en) * | 2001-12-19 | 2010-07-27 | University Of Massachusetts | Polysaccharide-containing block copolymer particles and uses thereof |
US20100266638A1 (en) | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
US9078892B2 (en) * | 2004-02-26 | 2015-07-14 | Allergan, Inc. | Methods for treating pain and for treating a medication overuse disorder |
KR101284710B1 (ko) * | 2004-03-03 | 2013-07-23 | 레반스 테라퓨틱스, 아이엔씨. | 국소 진단제 및 치료제의 수송을 위한 조성물 및 방법 |
CN1946431B (zh) * | 2004-03-03 | 2011-12-07 | 雷文斯治疗公司 | 用于肉毒毒素的局部施用和透皮递送的组合物和方法 |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
CA2799413A1 (en) * | 2004-07-26 | 2006-02-23 | Merz Pharma Gmbh & Co. Kgaa | Therapeutic composition with a botulinum neurotoxin |
EP1856139B1 (en) | 2005-03-03 | 2011-04-27 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of an oligopeptide |
BRPI0608249A2 (pt) | 2005-03-03 | 2009-12-08 | Revance Therapeutics Inc | formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica |
JP5368793B2 (ja) | 2005-07-18 | 2013-12-18 | ユニバーシティ オブ マサチューセッツ ロウエル | ナノエマルジョンを製造および使用するための組成物および方法 |
AU2013202329B2 (en) * | 2005-10-06 | 2016-04-14 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
US8137677B2 (en) * | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
JP4944896B2 (ja) * | 2005-11-17 | 2012-06-06 | ルバンス セラピュティックス インク. | 低減された非毒素タンパク質を含むボツリヌス毒素の局所適用及び経皮送達のための組成物及び方法 |
US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
TR201901443T4 (tr) | 2005-12-01 | 2019-02-21 | Univ Massachusetts Lowell | Botulinum nanoemülsiyonları. |
AR061669A1 (es) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
US20080063732A1 (en) * | 2006-07-31 | 2008-03-13 | Hantash Basil M | Method of increasing the efficacy of neurotoxin |
JP5345532B2 (ja) * | 2006-08-02 | 2013-11-20 | ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ | Lct中毒に対する医薬品 |
BRPI0719732A2 (pt) | 2006-12-01 | 2017-05-16 | Anterios Inc | nanopartículas de peptídeo e usos para as mesmas |
EP2494958A1 (en) * | 2006-12-01 | 2012-09-05 | Anterios, Inc. | Amphiphilic Entity Nanoparticles |
JP2010514779A (ja) * | 2006-12-29 | 2010-05-06 | ルバンス セラピュティックス インク. | 逆配列hiv−tatポリペプチドを用いる輸送分子 |
BRPI0720730A2 (pt) * | 2006-12-29 | 2014-04-08 | Revance Therapeutics Inc | Composições e métodos de aplicação tópica e liberação transdérmica de toxinas botulínicas estabilizadas com fragmentos de polipeptídeo derivados de hiv-tat. |
ES2660906T3 (es) | 2007-05-31 | 2018-03-26 | Anterios, Inc. | Nanopartículas de ácido nucleico y usos de las mismas |
EP2048156A1 (en) * | 2007-10-12 | 2009-04-15 | Merz Pharma GmbH & Co.KGaA | Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin |
CA2686642A1 (en) * | 2007-06-01 | 2008-12-04 | Merz Pharma Gmbh & Co. Kgaa | Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin |
CA2690773C (en) * | 2007-07-10 | 2013-09-17 | Medy-Tox, Inc. | Pharmaceutical liquid composition of botulinum toxin with improved stability |
DE102007038015A1 (de) * | 2007-08-10 | 2009-02-19 | Hefter, Harald, Prof. Dr. med. Dr. rer. nat. | Verwendung eines Neurotoxins |
SI2198007T1 (en) * | 2007-09-14 | 2018-04-30 | Sanofi Pasteur Biologics, Llc | Pharmaceutical compositions containing Clostridium difficile A and B toxoids |
US9161970B2 (en) * | 2007-12-12 | 2015-10-20 | Allergan, Inc. | Dermal filler |
US9044477B2 (en) * | 2007-12-12 | 2015-06-02 | Allergan, Inc. | Botulinum toxin formulation |
EP2072039A1 (en) * | 2007-12-21 | 2009-06-24 | Merz Pharma GmbH & Co.KGaA | Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects |
US9107815B2 (en) | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
KR20090124421A (ko) | 2008-05-30 | 2009-12-03 | 현대자동차주식회사 | 자동 변속기용 주차 브레이크 장치 |
WO2009158687A1 (en) * | 2008-06-26 | 2009-12-30 | Anterios, Inc. | Dermal delivery |
WO2010090677A1 (en) * | 2008-12-10 | 2010-08-12 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
SG172812A1 (en) | 2008-12-31 | 2011-08-29 | Revance Therapeutics Inc | Injectable botulinum toxin formulations |
JP5688031B2 (ja) | 2009-01-07 | 2015-03-25 | ロバート ジョン ペトレラ, | ヒアルロン酸およびボツリヌス毒素を使用する軟組織傷害の治療 |
AU2010214834B2 (en) * | 2009-02-19 | 2016-04-14 | Merz Pharma Gmbh & Co. Kgaa | Means and methods for manufacturing highly pure neurotoxin |
EP2248518B1 (en) * | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
KR102328155B1 (ko) * | 2009-06-25 | 2021-11-17 | 레반스 테라퓨틱스, 아이엔씨. | 알부민불포함 보툴리눔 독소 제제 |
ES2693705T3 (es) | 2009-07-02 | 2018-12-13 | Merz Pharma Gmbh & Co. Kgaa | Neurotoxinas que muestran actividad biológica reducida |
US8129139B2 (en) | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
JP2013545504A (ja) * | 2010-10-06 | 2013-12-26 | アラーガン、インコーポレイテッド | ボツリヌス毒素の貯蔵およびその後の取り扱いのためのシステム |
CA2814054A1 (en) | 2010-10-12 | 2012-04-19 | Merz Pharma Gmbh & Co. Kgaa | Formulation suitable for stabilizing proteins, which is free of mammalian excipients |
WO2012103415A1 (en) * | 2011-01-28 | 2012-08-02 | Allergan, Inc. | Dosage regimen for the treatment of multiple disorders with botulinum toxins |
WO2013068476A1 (en) | 2011-11-09 | 2013-05-16 | Merz Pharma Gmbh & Co. Kgaa | Neurotoxins exhibiting shortened biological activity |
US10980865B2 (en) * | 2012-08-10 | 2021-04-20 | Aquavit Pharmaceuticals, Inc. | Direct application system and method for the delivery of bioactive compositions and formulations |
US10894062B2 (en) | 2012-08-10 | 2021-01-19 | Aquavit Pharmaceuticals, Inc. | Vitamin supplement compositions for injection |
WO2014066916A2 (en) | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and methods for safe treatment of rhinitis |
DK2948174T3 (da) | 2013-01-28 | 2019-12-02 | Univ New York | Fremgangsmåder til behandling under anvendelse af atoksiske neurotoksinderivater |
KR20140147950A (ko) * | 2013-06-20 | 2014-12-31 | 서울대학교산학협력단 | 필러와 보틀리눔 독소를 포함하는 피부 주름, 노화 개선 또는 신경근육 관련 질환 치료용 조성물 |
LT3014267T (lt) | 2013-06-28 | 2018-12-10 | Merz Pharma Gmbh & Co. Kgaa | Priemonės ir būdai, skirti neurotoksinių polipeptidų nustatymui |
KR101339349B1 (ko) * | 2013-08-02 | 2013-12-09 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
WO2015024503A1 (en) * | 2013-08-21 | 2015-02-26 | The Hong Kong Polytechnic University | Engineering clostridia neurotoxins with elevated catalytic activity |
US9480731B2 (en) | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
CA2969463A1 (en) | 2014-12-09 | 2016-06-16 | New York University | Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use |
AU2015367329B2 (en) | 2014-12-19 | 2021-02-18 | Merz Pharma Gmbh & Co. Kgaa | Means and methods for the determination of the biological activity of BoNT/E in cells |
US11969461B2 (en) * | 2016-03-02 | 2024-04-30 | Merz Pharma Gmbh & Co. Kgaa | Composition comprising botulinum toxin |
WO2017188618A1 (en) * | 2016-04-26 | 2017-11-02 | Korea Prime Pharm Co., Ltd. | A novel composition comprising botulinum toxin |
KR102423739B1 (ko) * | 2016-05-27 | 2022-07-21 | 입센 바이오팜 리미티드 | 트립토판 또는 타이로신으로 안정화된 액체 신경독 제형 |
WO2018038301A1 (en) * | 2016-08-26 | 2018-03-01 | Hugel Inc. | Stabilized liquid formulation of botulinum toxin and preparation method thereof |
EP3290437A1 (en) | 2016-08-31 | 2018-03-07 | Merz Pharma GmbH & Co. KGaA | Novel recombinant clostridial neurotoxins with decreased duration of effect |
JP7217700B2 (ja) | 2016-09-13 | 2023-02-03 | アラーガン、インコーポレイテッド | 安定化非タンパク質クロストリジウム毒素組成物 |
EP3312193A1 (en) | 2016-10-19 | 2018-04-25 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with accelerated onset of effect |
KR102487144B1 (ko) | 2016-11-21 | 2023-01-12 | 에이리온 테라퓨틱스, 인코포레이티드 | 큰 물질의 경피 전달 |
EP3333179A1 (en) | 2016-12-07 | 2018-06-13 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum toxin with accelarated onset of effect |
EP3335719A1 (en) | 2016-12-14 | 2018-06-20 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with a stabilized light chain |
IL304733B1 (en) | 2017-03-24 | 2024-04-01 | Merz Pharma Gmbh & Co Kgaa | Improved use of botulinum toxin to treat sialorrhea |
US11952601B2 (en) | 2017-06-20 | 2024-04-09 | Merz Pharma Gmbh & Co. Kgaa | Recombinant botulinum toxin with increased duration of effect |
AU2018290765A1 (en) * | 2017-06-26 | 2020-01-23 | Bonti, Inc. | Clostridial neurotoxin formulations and use |
ES2930237T3 (es) | 2017-07-06 | 2022-12-09 | Merz Pharma Gmbh & Co Kgaa | Neurotoxinas botulínicas recombinantes nuevas con mayor duración de efectos |
KR20190038292A (ko) | 2017-09-29 | 2019-04-08 | 한국프라임제약주식회사 | 효능 지속시간이 연장된 보툴리눔 독소 조성물 |
WO2019081022A1 (en) | 2017-10-26 | 2019-05-02 | Merz Pharma Gmbh & Co. Kgaa | NOVEL RECOMBINANT BOTULINUM NEUROTOXINS WITH INCREASED DURATION |
WO2019101308A1 (en) | 2017-11-22 | 2019-05-31 | Merz Pharma Gmbh & Co. Kgaa | Novel recombinant botulinum toxin with increased duration of effect |
KR102274232B1 (ko) | 2018-08-28 | 2021-07-08 | 성균관대학교산학협력단 | 신경세포 표적용 단백질 조성물 |
GB201815844D0 (en) * | 2018-09-28 | 2018-11-14 | Ipsen Biopharm Ltd | Therapeutic & comestic uses of botulinum neurotoxin serotype e |
US20210393748A1 (en) | 2018-10-02 | 2021-12-23 | Merz Pharma Gmbh & Co. Kgaa | Novel uses of botulinum neurotoxin for treating lipoedema |
JP2022521237A (ja) | 2019-02-21 | 2022-04-06 | メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン | 振戦治療のためのボツリヌス神経毒素の新規用途 |
US11202753B1 (en) | 2020-03-06 | 2021-12-21 | Aquavit Pharmaceuticals, Inc. | Systems and methods for generating immune responses in subjects using microchannel delivery devices |
CA3177835A1 (en) | 2020-06-05 | 2021-12-09 | Susanna ROLL | High dose and low volume botulinum toxin treatment of facial wrinkles |
KR20230007129A (ko) | 2021-07-05 | 2023-01-12 | 주식회사 파마리서치바이오 | 클로스트리디움 보툴리눔 독소 복합체 단백질의 정제방법 |
KR20230009178A (ko) | 2021-07-08 | 2023-01-17 | 주식회사 파마리서치바이오 | 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법 |
WO2023085849A1 (ko) * | 2021-11-15 | 2023-05-19 | (주)메디톡스 | 보툴리눔 독소 조성물 |
TW202400122A (zh) | 2022-02-28 | 2024-01-01 | 德商梅茲製藥有限兩合公司 | 肉毒桿菌毒素用於降低皮膚毛孔尺寸及/或皮脂產生之用途、以及降低皮膚毛孔尺寸及/或皮脂產生的方法 |
KR102551301B1 (ko) | 2022-10-28 | 2023-07-03 | 주식회사 파마리서치바이오 | 보툴리눔 독소를 포함하는 안정한 액상 제제 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZW14486A1 (en) | 1985-07-29 | 1986-10-22 | Smithkline Beckman Corp | Pharmaceutical dosage unit |
GB8816443D0 (en) * | 1988-07-11 | 1988-08-17 | Albright & Wilson | Liquid enzymatic detergents |
US5215743A (en) * | 1988-04-13 | 1993-06-01 | Maninder Singh | Tumor necrosis factor formulations |
JPH03479A (ja) | 1989-05-25 | 1991-01-07 | Hitachi Ltd | プラズマ溶接装置及び溶接方法 |
JPH034791A (ja) * | 1989-05-30 | 1991-01-10 | Kanebo Ltd | 酵素の安定化方法 |
JP3504721B2 (ja) | 1994-05-09 | 2004-03-08 | エアバックス インターナショナル リミティド | 袋織エアバッグ |
US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
US5756468A (en) * | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
ES2237789T3 (es) | 1996-01-31 | 2005-08-01 | Cosmoferm B.V. | Utilizacion de composiciones que comprenden enzimas estabilizantes. |
TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
US20120238504A1 (en) * | 1998-09-11 | 2012-09-20 | Solstice Neurosciences, Llc | Stable Formulations of Botulinum Toxin in Hydrogels |
DE19925739A1 (de) * | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
PT1253932E (pt) | 2000-02-08 | 2005-07-29 | Allergan Inc | Composicoes farmaceuticas de toxina botulinica |
US8632785B2 (en) * | 2000-02-08 | 2014-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical composition containing a gelatin fragment |
JP4711520B2 (ja) * | 2000-03-21 | 2011-06-29 | 日本ケミカルリサーチ株式会社 | 生理活性ペプチド含有粉末 |
US20040033241A1 (en) * | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
US6645526B2 (en) * | 2001-11-13 | 2003-11-11 | Mylan Pharmaceuticals, Inc. | Storage stable thyroxine active drug formulations and methods for their production |
US7820194B2 (en) * | 2001-12-21 | 2010-10-26 | Alcon, Inc. | Combinations of viscoelastics for use during surgery |
US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
US7491403B2 (en) * | 2002-12-20 | 2009-02-17 | Botulinum Toxin Research Associates | Pharmaceutical botulinum toxin compositions |
US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
SI21257A (sl) * | 2002-07-17 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Stabilni farmacevtski pripravek, ki vsebuje eritropoietin |
CA2799413A1 (en) * | 2004-07-26 | 2006-02-23 | Merz Pharma Gmbh & Co. Kgaa | Therapeutic composition with a botulinum neurotoxin |
US8926991B2 (en) * | 2005-06-14 | 2015-01-06 | Botulinum Toxin Research Associates, Inc. | Botulinum toxin and the treatment of primary disorders of mood and affect |
US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
US8137677B2 (en) * | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
US20090324647A1 (en) * | 2005-10-11 | 2009-12-31 | Borodic Gary E | Albumin-Free Botulinum Toxin Based Pharmaceutical Compositions Containing a Hyaluronidase and Methods of Use |
US20070154493A1 (en) * | 2005-12-30 | 2007-07-05 | Judy Hattendorf | Method of treating skin needing botulinum toxin type a treatment |
AU2010214834B2 (en) * | 2009-02-19 | 2016-04-14 | Merz Pharma Gmbh & Co. Kgaa | Means and methods for manufacturing highly pure neurotoxin |
EP2248518B1 (en) * | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
KR102328155B1 (ko) * | 2009-06-25 | 2021-11-17 | 레반스 테라퓨틱스, 아이엔씨. | 알부민불포함 보툴리눔 독소 제제 |
KR101788340B1 (ko) * | 2009-10-21 | 2017-10-19 | 메르츠 파마 게엠베하 운트 코. 카가아 | 미처리된 및 부분적으로 처리된 신경독 타입 a를 결정하기 위한 시스템 |
WO2011088993A1 (en) * | 2010-01-22 | 2011-07-28 | Merz Pharma Gmbh & Co. Kgaa | In vitro assay for quantifying clostridial neurotoxin activity |
WO2011103465A2 (en) * | 2010-02-20 | 2011-08-25 | Alexey Gennadievich Zdanovsky | Botulinum neurotoxin antigenic compositions and methods |
US20120201857A1 (en) * | 2010-03-17 | 2012-08-09 | Pankaj Modi | Transdermal delivery system for therapeutics |
CA2814054A1 (en) * | 2010-10-12 | 2012-04-19 | Merz Pharma Gmbh & Co. Kgaa | Formulation suitable for stabilizing proteins, which is free of mammalian excipients |
ES2810098T3 (es) * | 2011-03-31 | 2021-03-08 | Medy Tox Inc | Preparación liofilizada de toxina botulínica |
EP2694975A1 (en) * | 2011-04-08 | 2014-02-12 | Biogen Idec MA Inc. | Biomarkers predictive of therapeutic responsiveness to ifnbeta and uses thereof |
JP6236332B2 (ja) | 2014-02-24 | 2017-11-22 | ホシザキ株式会社 | 冷温蔵装置 |
-
2005
- 2005-07-19 CA CA2799413A patent/CA2799413A1/en not_active Abandoned
- 2005-07-19 ES ES10181506.6T patent/ES2479515T3/es active Active
- 2005-07-19 US US11/184,495 patent/US7879341B2/en active Active
- 2005-07-19 AU AU2005274822A patent/AU2005274822B2/en active Active
- 2005-07-19 MX MX2007000794A patent/MX2007000794A/es active IP Right Grant
- 2005-07-19 CN CN2005800282064A patent/CN101005853B/zh active Active
- 2005-07-19 BR BRPI0513850-7A patent/BRPI0513850A/pt not_active Application Discontinuation
- 2005-07-19 EP EP10184484.3A patent/EP2266600B1/en active Active
- 2005-07-19 KR KR1020087012497A patent/KR100852824B1/ko active IP Right Grant
- 2005-07-19 EP EP05765454.3A patent/EP1786459B1/en active Active
- 2005-07-19 KR KR1020087012496A patent/KR100852821B1/ko active IP Right Grant
- 2005-07-19 CN CN2011100729910A patent/CN102139099A/zh active Pending
- 2005-07-19 EP EP10181506.6A patent/EP2266599B1/en active Active
- 2005-07-19 CA CA2578250A patent/CA2578250C/en not_active Expired - Fee Related
- 2005-07-19 EA EA200700213A patent/EA011652B1/ru not_active IP Right Cessation
- 2005-07-19 JP JP2007523628A patent/JP4907530B2/ja active Active
- 2005-07-19 KR KR1020077001912A patent/KR100852822B1/ko active IP Right Grant
- 2005-07-19 WO PCT/US2005/025408 patent/WO2006020208A2/en active Application Filing
-
2007
- 2007-01-15 ZA ZA200700433A patent/ZA200700433B/en unknown
- 2007-01-17 IL IL180771A patent/IL180771A/en not_active IP Right Cessation
- 2007-01-25 EC EC2007007197A patent/ECSP077197A/es unknown
- 2007-02-23 NO NO20071043A patent/NO20071043L/no not_active Application Discontinuation
- 2007-12-05 HK HK07113262.7A patent/HK1107670A1/xx unknown
-
2010
- 2010-10-15 JP JP2010232458A patent/JP2011016846A/ja active Pending
- 2010-12-22 US US12/928,898 patent/US8372645B2/en active Active
-
2012
- 2012-05-20 IL IL219897A patent/IL219897A0/en unknown
-
2013
- 2013-01-10 US US13/738,283 patent/US8652489B2/en active Active
- 2013-03-07 JP JP2013045137A patent/JP2013107904A/ja not_active Withdrawn
- 2013-04-18 IL IL225848A patent/IL225848A0/en unknown
- 2013-12-19 US US14/134,505 patent/US9050367B2/en active Active
-
2015
- 2015-05-05 US US14/704,320 patent/US9220783B2/en active Active
- 2015-11-24 US US14/950,587 patent/US10105421B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0513850A (pt) | composição terapêutica com uma neurotoxina botulìnica | |
BR112014022708A8 (pt) | uso de uma proteína ligante de neurotrofina p75ntr, uso de uma molécula de ácido nucleico, uso de um vetor de expressão replicável, célula hospedeira, composição farmacêutica e kit | |
BRPI0614761A2 (pt) | proteìnas de fusão de albumina | |
BRPI0607326B8 (pt) | composição de vacina, uso da referida composição e kit em partes | |
ECSP099332A (es) | Moléculas de enlace de lingo y uso farmacéutico de las mismas | |
ES2353814T3 (es) | Proteinas n-glicosiladas recombinantes de celulas procariotas. | |
ATE548381T1 (de) | Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus | |
DK1796646T3 (da) | Kosmetiske neurotoksinsammensætninger omfattende en botulinumtoksinbestanddel samt tilhörende fremgangsmåder | |
BRPI0512352A (pt) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas | |
BR112013010855A2 (pt) | luciferases derivadas de oplophorus, novos substratos de coelenterazina e métodos de uso | |
BR112016002753A2 (pt) | anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos | |
AR064706A1 (es) | Composiciones y metodos para aplicacion topica y suministro transdermico de toxinas de botulina estabilizadas con fragmentos de polipeptido derivados de hiv -tat | |
MX2009002816A (es) | Proteinas de fusion de albumina. | |
BR112014024282A2 (pt) | anticorpos ligantes ao receptor b1 da bradicinina | |
BR112012017345A2 (pt) | "composições e métodos de pgl para a produção aumentada de isopreno e outros produtos com 6-fosfogliconolactonase (pgl)" | |
BRPI0508670A (pt) | proteìnas de buganina modificada, citotoxinas e métodos e usos delas | |
CO2022016595A2 (es) | Nuevas proteinas de unión a repeticiones de anquirina y sus usos | |
ATE500265T1 (de) | Synthetische mecp2-sequenz für die proteinersatztherapie | |
EA200802307A1 (ru) | Бинарные смеси гиалуроновой кислоты и их терапевтическое применение | |
BRPI0517843A (pt) | compostos de moléculas conjugadas com a atividade de absorção de células aumentada | |
ATE522541T1 (de) | Bakterielle adhäsine konformere | |
BRPI0616936B8 (pt) | composição farmacêutica | |
BR122018077204B8 (pt) | peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica | |
FR2896693B1 (fr) | Composition comprenant plusieurs toxines botuliques | |
BRPI0518891A2 (pt) | composiÇço farmacÊutica àptica tàpica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |